|
Patent landscape, scope, and claims: |
US Patent 12,558,317: Scope, Claim Architecture, and Patent-Landscape Implications
What does US 12,558,317 actually claim?
US Patent 12,558,317 claims a specific three-component pharmaceutical composition built around:
- Xanomeline (or a pharmaceutically acceptable salt, with xanomeline tartrate called out in dependent claims)
- Trospium chloride
- 3-[(4-hexyloxy)-1,2,5-thiadiazol-3-yl]-5-hydroxyl-1-methylpyridin-1-ium (the “3-[(4-hexyloxy)...] pyridinium” component)
Independent claim (anchor of enforceable subject matter)
Claim 1 is the core composition definition:
- A pharmaceutical composition comprising:
- xanomeline (or salt)
- trospium chloride
- 3-[(4-hexyloxy)-1,2,5-thiadiazol-3-yl]-5-hydroxyl-1-methylpyridin-1-ium
Everything else narrows or operationalizes Claim 1 by imposing:
- tight wt.% ranges for the pyridinium component,
- two-component (multi-part) formulation structure (first component vs second component),
- stability limits after storage (3 months at 40°C/75% RH),
- bead-based solid structure plus acid dissolution rate performance,
- and optional antioxidant formulation.
How is the claim set structured (scope by layers)?
The claims follow a layered “base composition + narrowing features” structure. The repetition is deliberate: the patent drafts multiple dependent claim chains to preserve coverage even if a competitor targets one sub-feature (dose level, stability, excipients, beads, dissolution kinetics, antioxidant inclusion).
Scope layer map
Layer A: Core composition
- Claim 1: xanomeline (salt) + trospium chloride + the pyridinium component.
Layer B: Amount / concentration of pyridinium
- Generic wt.% limits appear throughout:
- < 0.25 wt.% (Claims 2, 7, 13, 19, 39, 40, 48, 55, 62)
- 0.1 to 0.25 wt.% (Claims 3, 7, 13, 19, 25, 32, 40, 48, 55, 62)
- < 0.2 wt.% (Claims 4, 8, 14, 20, 26, 33, 41, 49, 56, 63)
- 0.1 to 0.2 wt.% (Claims 5, 9, 15, 21, 27, 34, 42, 50, 57, 64)
- Post-storage stability limit: < 0.5 wt.% after 3 months at 40°C and 75% RH (Claims 10, 16, 22, 28, 35, 44, 51, 58, 65, 73, 74, 76)
Layer C: Two-component formulation architecture
- Claims 6 and 43 define a two-part setup:
- First component: xanomeline (and optional antioxidant)
- Second component: trospium chloride
- The pyridinium component is integrated into the overall pharmaceutical composition, and dependent claims pin down wt.% and stability.
Layer D: Solid-state composition details (excipients)
- Claims 18 and 54:
- first component includes microcrystalline cellulose
- second component includes microcrystalline cellulose, lactose, or a combination.
Layer E: Bead-based multipart structure
- Claims 24 and 61:
- first component is a first plurality of beads
- second component is a second plurality of beads
Layer F: Dissolution performance requirement (acid dissolution kinetics)
- Claims 30 and 37 and 68:
- beads (first and second pluralities) have dissolution rate > about 80% within first 30 minutes
- measured in 0.1 N HCl solution.
Layer G: Antioxidant variant
- Claims 38 onward introduce an optional antioxidant layer:
- Claim 38: composition further comprises an antioxidant
- Claims 45 and 52 specify ascorbic acid
- Claims 43, 44, 47, 52, 59, 60, 66, 67, 68 map the antioxidant into the first component, with associated stability and wt.% restrictions.
What are the practical boundaries of Claim 1’s composition (what must be present)?
Claim 1 requires all three actives/components in the same pharmaceutical composition:
- Xanomeline or salt
- Trospium chloride
- 3-[(4-hexyloxy)-1,2,5-thiadiazol-3-yl]-5-hydroxyl-1-methylpyridin-1-ium
That makes Claim 1 a high-friction claim for design-around:
- If a competitor omits the pyridinium component, it misses Claim 1.
- If a competitor replaces trospium chloride with another antimuscarinic, it misses Claim 1.
- If a competitor avoids xanomeline (or avoids xanomeline salt), it misses Claim 1.
Dependent claims then tighten tolerances for the pyridinium component and enforce performance/stability related attributes.
How do the wt.% dependent claims affect freedom-to-operate (FTO)?
The dependent claims create multiple enforceable “windows.” Even if a competitor hits the general composition but changes the concentration of the pyridinium component, the competitor must avoid:
- all <0.25, 0.1-0.25, <0.2, 0.1-0.2 thresholds across the claim set,
- and the specific stability after storage requirement that caps the pyridinium component at <0.5 wt.% after 3 months at 40°C/75% RH.
Concentration table (as pleaded in the claim set)
| Constraint type |
Limit |
Claims (examples in set) |
| Upper bound |
<0.25 wt.% |
2, 7, 13, 19, 39, 48, 55, 62 |
| Window |
0.1 to 0.25 wt.% |
3, 7, 13, 19, 25, 32, 40, 48, 55, 62 |
| Upper bound |
<0.2 wt.% |
4, 8, 14, 20, 26, 33, 41, 49, 56, 63 |
| Window |
0.1 to 0.2 wt.% |
5, 9, 15, 21, 27, 34, 42, 50, 57, 64 |
| Storage-stability cap |
<0.5 wt.% after 3 months at 40°C/75% RH |
10, 16, 22, 28, 35, 44, 51, 58, 65, 73, 76 |
Key enforcement dynamic: the patent does not rely on one concentration window. It asserts multiple overlapping ranges and upper bounds, increasing the probability that a generic “small amount” formulation lands inside at least one dependent claim.
What does the two-component (bead/parts) architecture do to design-around?
Claims 6 and 43 define the product as two formulated components:
- First component: xanomeline (salt) and optionally antioxidant
- Second component: trospium chloride
Dependent claims then further specify that the components are:
- microcrystalline-cellulose/lactose excipient-based (Claims 18, 31, 54, 69)
- packaged as bead pluralities (Claims 24, 61)
- with acid dissolution rate > about 80% in first 30 minutes (Claims 30, 37, 68)
This matters because a competitor can more easily reformulate dose or add/remove excipients than it can restructure a solid dosage form into a bead-based multipart dissolution system that reproduces the same kinetics.
How broad are the dissolution-performance claims?
The dissolution limitation is narrow in test conditions but broad in performance statement:
- Dissolution media: 0.1 N HCl
- Time window: first 30 minutes
- Performance: dissolution rate > about 80%
Applied to bead pluralities in both first and second components (Claims 30, 37, 68), this can be a meaningful barrier for alternatives such as:
- immediate-release tablets using different matrices,
- differently coated beads that change dissolution kinetics,
- or formulations that separate actives without meeting the stated dissolution threshold.
What is the antioxidant variant and how does it expand coverage?
Claim 38 adds an optional antioxidant.
- Claim 45 and 52 specify ascorbic acid.
- Claims 43 and 47 place antioxidant into the first component while trospium chloride remains in the second.
Dependent chains then reassert:
- the same pyridinium concentration ranges,
- the same stability after storage limit (<0.5 wt.% after 3 months at 40°C/75% RH),
- and (in later claims) the same bead and dissolution performance language.
Net effect: the patent captures both antioxidant-containing and antioxidant-free implementations, without losing the core three-component requirement.
What is the overall patent-landscape implication for competitors?
Based on the claim text alone, US 12,558,317 is not positioned as a “single-mechanism” novelty claim. It is positioned as a formulation system patent with multiple enforceable hooks:
- Composition hook (Claim 1): xanomeline + trospium chloride + specific pyridinium compound.
- Dose/amount hooks: repeated wt.% caps and windows.
- Stability hook: pyridinium limit after forced storage (40°C/75% RH for 3 months).
- Architecture hook: two-part formulation (first vs second component).
- Solid-form hook: bead pluralities with excipient-specific examples.
- Performance hook: rapid dissolution (>80% in 30 minutes at 0.1 N HCl).
- Optionality hook: antioxidant (ascorbic acid) in first component.
Likely invalidity and design-around pressure points (from scope, not from prosecution history)
- Claim 1 is broad, so any competitor attempting a similar combination risks infringement if it also uses the specified pyridinium component.
- Design-around by concentration is hard because the patent asserts overlapping ranges rather than one “exact” amount.
- Design-around by formulation structure is hard because multiple dependent claims enforce bead architecture and dissolution kinetics.
- Design-around by antioxidant is partially ineffective because the antioxidant is optional; removal of antioxidant likely does not eliminate coverage if the other features still meet the claimed composition/subcombinations.
What claims are “most likely to matter” for litigation or licensing leverage?
In practice, the high-value leverage points are usually:
- Claim 1 for baseline infringement capture.
- Dependent claims that narrow to commercially plausible formulations:
- wt.% ranges (0.1-0.2, 0.1-0.25, and <0.2/<0.25),
- stability (post-storage <0.5 wt.%),
- bead/dissolution performance (>80% in 30 minutes at 0.1 N HCl),
- and antioxidant (ascorbic acid) if that matches a marketed or planned product.
From the claim set provided, the “most litigatable” dependent clusters are:
- Claims 24 + 30 and Claims 61 + 68 (beads + rapid acid dissolution),
- Claims 10/16/22/28/35/44/51/58/65/73/76 (stability limit),
- Claims 2-5 and 4/5/8-9/14-15 etc. (dose windows),
- Claims 38 + 45/52 (ascorbic acid variants).
Can you map the independent claim footprint to product development decisions?
Yes. The claim set forces development choices into a small set of “safe harbors”:
- If a product uses xanomeline + trospium chloride but chooses a different third component, it avoids Claim 1.
- If it uses the same third component but changes its concentration outside all asserted ranges and avoids the stability cap after 3 months at 40°C/75% RH, it may avoid dependent coverage, though Claim 1 remains a risk if the concentration still counts and Claim 1 does not require a concentration limit.
- If it uses the same three components but alters the solid structure and dissolution kinetics, it can potentially avoid dependent bead/dissolution claims, but Claim 1 still remains.
- If it avoids the multi-part bead structure and does not include the relevant excipient patterns (microcrystalline cellulose and lactose combinations in second component), it can potentially reduce dependent claim coverage, but again Claim 1 can still be asserted.
Key Takeaways
- US 12,558,317 is anchored by Claim 1, which requires a specific combination: xanomeline (or salt) + trospium chloride + a specified pyridinium compound.
- The dependent claims stack multiple concentration windows (0.1-0.2, 0.1-0.25, plus upper bounds <0.2 and <0.25) for that pyridinium component.
- The patent adds formulation-system constraints: two-component first/second formulation, bead pluralities, microcrystalline cellulose/lactose excipient patterns, and acid dissolution performance (>80% within 30 minutes in 0.1 N HCl).
- A stability limitation caps the pyridinium component at <0.5 wt.% after 3 months at 40°C/75% RH, creating a testable limitation that can block certain formulation changes.
- The antioxidant branch expands coverage to antioxidant-containing variants, with ascorbic acid specified.
FAQs
1) What determines infringement for the broadest coverage?
Claim 1: the product must contain xanomeline (or salt), trospium chloride, and 3-[(4-hexyloxy)-1,2,5-thiadiazol-3-yl]-5-hydroxyl-1-methylpyridin-1-ium in the same pharmaceutical composition.
2) Do the wt.% limits matter if Claim 1 is asserted?
Yes for dependent claims. Claim 1 does not state a wt.% limitation in the provided claim text, so wt.% primarily drives risk under dependent claims that explicitly cap or window the pyridinium component.
3) What formulation feature is repeatedly used to narrow scope?
Two-component architecture with first component vs second component, often implemented as bead pluralities and linked to a dissolution rate requirement in 0.1 N HCl.
4) How does the patent treat storage stability?
It adds a specific stability constraint: the pyridinium component must be <0.5 wt.% after 3 months at 40°C and 75% relative humidity (applies in multiple dependent chains).
5) Does adding an antioxidant change the infringement risk?
It can expand it. The patent includes an antioxidant-dependent branch, with ascorbic acid explicitly recited, and it ties that antioxidant to the first component while still maintaining the core three-component composition requirement.
References
No external sources were cited because the provided prompt contains only the claim text and does not include bibliographic metadata (publication number, assignee, filing date, priority date, prosecution history) or any links to the patent document needed for landscape mapping.
More… ↓
⤷ Start Trial
|
